Fred Alger Management, LLC Fate Therapeutics Inc Transaction History

Fred Alger Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $1.07 Million - $1.74 Million	-14,837 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$38.09 - $100.95 $507,587 - $1.35 Million	-13,326 Reduced 47.32%	14,837 $1.35 Million
Q3 2020 Nov 13, 2020	SELL	$30.41 - $40.5 $152,141 - $202,621	-5,003 Reduced 15.08%	28,163 $1.13 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $104,404 - $181,998	5,166 Added 18.45%	33,166 $1.14 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $345,600 - $637,600	-20,000 Reduced 41.67%	28,000 $622,000
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $107,120 - $165,840	8,000 Added 20.0%	48,000 $939,000
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $464,100 - $675,000	30,000 Added 300.0%	40,000 $621,000
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $156,100 - $204,400	10,000 New	10,000 $203,000
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $126,280 - $186,780	-11,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $96,250 - $179,190	11,000 New	11,000 $179,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Fred Alger Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fred Alger Management, LLC with notifications on news.